These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 392593)
1. Advances in the use of iron-chelating agents for the treatment of iron overload. Modell B Prog Hematol; 1979; 11():267-312. PubMed ID: 392593 [No Abstract] [Full Text] [Related]
2. Recognition and treatment of iron overload. Brown EB Adv Intern Med; 1980; 26():159-86. PubMed ID: 7013439 [No Abstract] [Full Text] [Related]
3. Medical management of beta-thalassemia. Lerner N Prog Clin Biol Res; 1989; 309():13-22. PubMed ID: 2780747 [No Abstract] [Full Text] [Related]
5. [Chelating therapy in beta-thalassemia]. Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040 [TBL] [Abstract][Full Text] [Related]
6. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547 [TBL] [Abstract][Full Text] [Related]
13. [Serum ferritin in the follow-up of homozygotic beta-thalassemia treated with blood transfusion and iron-chelating agents]. Esposito L; Ferrara M; Ponte G Pediatria (Napoli); 1981 Sep; 89(3):479-92. PubMed ID: 7346759 [No Abstract] [Full Text] [Related]
14. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report. Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548 [No Abstract] [Full Text] [Related]
15. [Contribution to the problem of hemochromatosis]. Bruns W; Michaelis D; Takác A; Langsch HG Dtsch Z Verdau Stoffwechselkr; 1966 Feb; 25(6):363-70. PubMed ID: 5998360 [No Abstract] [Full Text] [Related]
16. Reassessment of the use of desferrioxamine B in iron overload. Propper RD; Shurin SB; Nathan DG N Engl J Med; 1976 Jun; 294(26):1421-3. PubMed ID: 1272274 [TBL] [Abstract][Full Text] [Related]
17. Desferal therapy in iron storage disease. Thompson RB; Owen DM; Bell WN Am J Med Sci; 1967 Apr; 253(4):453-60. PubMed ID: 6021380 [No Abstract] [Full Text] [Related]
18. Liver iron overload and liver fibrosis in thalassemia. Angelucci E; Baronciani D; Lucarelli G; Giardini C; Galimberti M; Polchi P; Martinelli F; Baldassarri M; Muretto P Bone Marrow Transplant; 1993; 12 Suppl 1():29-31. PubMed ID: 8374556 [No Abstract] [Full Text] [Related]
19. Hepatic iron stores in thalassemia: non-invasive magnetic measurements. Brittenham GM; Allen CJ; Farrell DE; Harris JW Prog Clin Biol Res; 1989; 309():101-6. PubMed ID: 2780744 [No Abstract] [Full Text] [Related]
20. [Thalassemia major: chelating therapy with deferoxamine]. Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934 [No Abstract] [Full Text] [Related] [Next] [New Search]